# DELPHINUS (NCT03384654)

> A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03384654
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions: Daratumumab; Vincristine; Prednisone; Doxorubicin; Peg-asparaginase; Cyclophosphamide; Cytarabine; 6-mercaptopurine; Methotrexate
- Enrollment: 47
- Primary outcome: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
- Primary outcome: Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL

## Indexed commentary on DELPHINUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 3
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=delphinus-nct03384654

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03384654", "email": "<work email>"}; the inbox owner confirms by the emailed link.